public nasdaq targ industry biotechnology fate acquired successor the medicines company founded 1997 as phagetech inc. defunct 2009 2009 headquarters cambridge massachusetts number of employees 82 9 24 07 per s 1 website http www.themedicinescompany.com targanta therapeutics corporation was a biopharmaceutical company headquartered in cambridge massachusetts . the company also had operations in indianapolis montreal and toronto . targanta completed its initial public offering on october 9 2007 1 and trades on the nasdaq market under the symbol targ . targanta was acquired by the medicines company in 2009 . 2 development programs edit targanta s lead product candidate was oritavancin a novel semi synthetic glycopeptide antibiotic being developed to treat serious gram positive infections in the hospital and other institutional settings . oritavancin was originally discovered and developed by eli lilly ; targanta acquired worldwide rights to oritavancin from intermune in late 2005 . 3 data presented at the 47th annual interscience conference on antimicrobial agents and chemotherapy icaac in september 2007 demonstrated that oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible gram positive bacteria including staphylococcus aureus methicillin resistant staphylococcus aureus enterococci clostridium difficile and streptococci . 4 results have been presented but not yet published from two pivotal phase 3 clinical trials testing the efficacy of oritavancin for the treatment of complicated skin and skin structure infections csssi caused by gram positive bacteria . the primary endpoints of both studies were successfully met with oritavancin achieving efficacy with fewer days of therapy than the comparator agents vancomycin followed by cephalexin . in addition oritavancin showed a significantly improved safety profile with a 19.2 percent relative reduction in the overall incidence of adverse events versus vancomycin cephalexin p 0.001 in the second and larger pivotal trial . 5 targanta also developed a novel drug discovery platform to generate molecules that deliver antibiotics directly to the bone . also at the 47th icaac meeting in september 2007 targanta presented the first in vivo pre clinical data on candidates from this program demonstrating efficacy of its rifabutin bisphosphonate prodrug tt99000647 in a rabbit osteomyelitis model . 6 references edit ipo news archives the medicines company completes acquisition of targanta therapeutics corporation february 26 2009 targanta revives oritavancin next weapon against csssi bioworld today november 26 2007 icaac 2007 posters e 1612 in vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens e 1613 in vitro activity profile of oritavancin ori against organisms demonstrating key resistance profiles to other antimicrobial agents e 1614 in vitro time kill studies of oritavancin against drug resistant isolates of staphylococcus aureus and enterococci e 1615 anti enterococcal activity profile of oritavancin a potent lipoglycopeptide under development for use against gram positive infections e 1616 anti streptococcal activity profile of oritavancin a potent lipoglycopeptide under development for use against gram positive infections e 1617 in vitro activity profile of oritavancin ori against resistant staphylococcal populations from a recent surveillance initiative e 1620 pharmacokinetic concentrations of oritavancin kill stationary phase and biofilm staphylococcus aureus in vitro . targanta press release september 19 2007 icaac 2003 late breaker poster phase iii trial comparing 3 7 days of oritavancin vs. 10 14 days of vancomycin cephalexin in the treatment of patients with complicated skin and skin structure infections csssi intermune press release september 15 2003 icaac 2007 poster in vivo efficacy of a new osteotropic prodrug in a rabbit model of chronic osteomyelitis targanta press release september 19 2007 retrieved from https en.wikipedia.org w index.php title targanta therapeutics corporation & oldid 705215056 categories biotechnology companies of the united stateseli lilly and companycompanies formerly listed on nasdaqpharmaceutical companies established in 1997companies disestablished in 2009companies based in cambridge massachusettshidden categories pages using infobox company with unsupported parameters navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 16 february 2016 at 04 51 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view